OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Medicine Man Technologies Inc. (OTCQX: MDCL), a consulting business for those operating in the cannabis space, has qualified to trade on the OTCQX® Best Market. Medicine Man Technologies upgraded to OTCQX from the OTCQB® Venture Market.
Medicine Man Technologies begins trading today on OTCQX under the symbol “MDCL.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
“Medicine Man Technologies utilized our OTCQB Venture Market to build their valuation and liquidity as a public company,” said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. “We congratulate the company on graduating to our OTCQX Best Market and we look forward to supporting the company as they build long-term shareholder value.”
Brett Roper, CEO stated, “Since our first day of trading on the OTC Markets as an OTCQB company in January of 2016, we have focused on evolving to a point where we could qualify for OTCQX. OTCQX’s reporting and related requirements provided our company with a goal that we are excited to check off our list of most important things to get done. We found the application process very straight forward and would also like to thank our sponsor, Mr. Kenneth Sam of Dorsey and Whitney LLP for his guidance and support.”
Medicine Man Technologies was sponsored for OTCQX by Dorsey & Whitney LLP, a qualified third-party firm responsible for providing guidance on OTCQX requirements and recommending membership.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…